{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:31:03Z","timestamp":1786516263334,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Meropenem is a broad-spectrum carbapenem antibiotic widely used for severe infections; however, its real-world adverse event profile and age-stratified pharmacovigilance signals remain insufficiently characterized. This study aimed to evaluate signals of meropenem-associated adverse events using the FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      FAERS reports from 2004 Q1 to 2025 Q4 were extracted. Reports listing meropenem as the primary suspect drug were included after standardization and deduplication. Disproportionality analyses were performed at the Preferred Term (PT) level using the reporting odds ratio, proportional reporting ratio, empirical Bayes geometric mean, and information component, with a Bonferroni correction applied to PRR chi-square\n                      <jats:italic>P<\/jats:italic>\n                      -values for multiple PT-level comparisons. Reports were stratified into five age groups: &amp;lt; 18, 18\u201339, 40\u201359, 60\u201379, and \u226580 years. Age-, sex-, seriousness-, fatality-, and time-to-onset stratified analyses were conducted. A healthcare professional (HCP)-only subset analysis was performed using the same statistical framework.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 5,018 meropenem primary suspect drug-event records were identified, corresponding to 4,431 deduplicated report-level cases after merging FAERS DEMO, DRUG, and REAC tables. Overall, 254 PT-level signals remained significant after four-algorithm screening and Bonferroni correction. These signals were mainly distributed across infections and infestations, investigations, skin and subcutaneous tissue disorders, blood and lymphatic system disorders, and hepatobiliary disorders. Frequently detected PTs included pyrexia, acute kidney injury, pancytopenia, thrombocytopenia, septic shock, seizure, DRESS, multiple organ dysfunction syndrome, and sepsis. Age-stratified analysis showed a heterogeneous distribution of signals across age groups, with higher numbers of reports and signals observed in the 40\u201379-year age group. The proportion of reported serious outcomes increased across age strata, exceeding 85% among patients aged \u226540 years. Median time-to-onset was 5 days, and the Weibull shape parameter (\u03b2 = 0.72) suggested an early-reporting pattern of events. HCP-only analysis demonstrated consistent signal patterns compared with the primary analysis at the PT level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Meropenem-associated adverse event signals involved multiple organ systems and demonstrated heterogeneous distribution across age groups. Early-onset clustering was observed for several key signals. These findings represent FAERS-based disproportionality signals rather than causal associations and require further sclinical validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1890727","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:56:40Z","timestamp":1786514200000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world pharmacovigilance assessment of meropenem-associated adverse events: age stratification and time-to-onset analysis using FAERS"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaobin","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Zigong Fourth People's Hospital","place":["Zigong, Sichuan, China"]},{"name":"Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zigong First People's Hospital","place":["Zigong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Zigong Fourth People's Hospital","place":["Zigong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Zigong Fourth People's Hospital","place":["Zigong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13756-024-01367-8","article-title":"Healthcare-associated infections and antimicrobial use in acute care hospitals in Greece, 2022: results of the third point-prevalence survey","volume":"13","author":"Palaiopanos","year":"2024","journal-title":"Antimicrob Resist Infect Control."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1086\/590065","article-title":"Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections","volume":"1","author":"Mohr","year":"2008","journal-title":"Clin Infect Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2411092","DOI":"10.1002\/adma.202411092","article-title":"Transcytosable and ultrasound-activated liposome enables deep penetration of biofilm for surgical site infection management","volume":"37","author":"Wang","year":"2025","journal-title":"Adv Mater Deerfield Beach Fla."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1086\/590064","article-title":"Pharmacokinetic and pharmacodynamic properties of meropenem","volume":"1","author":"Nicolau","year":"2008","journal-title":"Clin Infect Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/cid\/ciae210","article-title":"Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis with Sulbactam-durlobactam","volume":"79","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/cid\/ciaf071","article-title":"The effectiveness of newer beta-lactams for the treatment of antimicrobial-resistant gram-negative meningitis","volume":"80","author":"Hsu","year":"2025","journal-title":"Clin Infect Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","article-title":"Meropenem: a review of its use in the treatment of serious bacterial infections","volume":"68","author":"Baldwin","year":"2008","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"R84","DOI":"10.1186\/cc12705","article-title":"Meropenem and piperacillin\/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic\/pharmacodynamic target attainment when extended infusions are used?","volume":"17","author":"Carlier","year":"2013","journal-title":"Crit Care Lond Engl."},{"key":"B9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s41038-019-0150-7","article-title":"Hypocoagulation induced by broad-spectrum antibiotics in extensive burn patients","volume":"7","author":"Liu","year":"2019","journal-title":"Burns Trauma."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1671455","DOI":"10.3389\/fmed.2025.1671455","article-title":"Case report: delayed-type hypersensitivity reaction to meropenem in an elderly patient-successful management with imipenem-cilastatin","volume":"12","author":"He","year":"2025","journal-title":"Front Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s00415-025-13067-3","article-title":"Neural correlates of \u03b2-lactam exposure in intensive care unit patients: an observational, prospective cohort study","volume":"272","author":"Zalta","year":"2025","journal-title":"J Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"B13","first-page":"497","article-title":"Elevated \u03b2-lactam concentrations associated with neurological deterioration in ICU septic patients","volume":"81","author":"Beumier","year":"2015","journal-title":"Minerva Anestesiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/pharmaceutics12090785","article-title":"Population pharmacokinetics of continuous-infusion meropenem in febrile neutropenic patients with hematologic malignancies: dosing strategies for optimizing empirical treatment against enterobacterales and P. aeruginosa","volume":"12","author":"Cojutti","year":"2020","journal-title":"Pharmaceutics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e02103","DOI":"10.1128\/AAC.02103-17","article-title":"Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment","volume":"62","author":"Rubino","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1292163","DOI":"10.3389\/fphar.2024.1292163","article-title":"Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events","volume":"15","author":"Huo","year":"2024","journal-title":"Front Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2165\/11597870-000000000-00000","article-title":"Antimicrobial prescribing in hospitalized adults stratified by age: data from the ESAC point-prevalence surveys","volume":"29","year":"2012","journal-title":"Drugs Aging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"18221","DOI":"10.1038\/s41598-024-69279-6","article-title":"An investigation of broad-spectrum antibiotic-induced liver injury based on the FDA adverse event reporting system and retrospective observational study","volume":"14","author":"Shiraishi","year":"2024","journal-title":"Sci Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s15010-025-02698-3","article-title":"Efficacy and safety of colistin-doxycycline combination therapy in multi-drug resistance Gram-negative infections: a double-blind randomized controlled trial","volume":"54","author":"Abaft","year":"2026","journal-title":"Infection"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00228-025-03910-x","article-title":"Population pharmacokinetics and pharmacodynamics of meropenem in critically ill patients with renal impairment or on continuous renal replacement therapy","volume":"81","author":"Feng","year":"2025","journal-title":"Eur J Clin Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40266-023-01019-3","article-title":"Safety and tolerability of antimicrobial agents in the older patient","volume":"40","author":"Soraci","year":"2023","journal-title":"Drugs Aging"},{"key":"B22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s41999-021-00481-9","article-title":"Adverse drug reactions in older adults: a narrative review of the literature","volume":"12","author":"Zazzara","year":"2021","journal-title":"Eur Geriatr Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40262-024-01465-1","article-title":"Population pharmacokinetics of meropenem across the adult lifespan","volume":"64","author":"Boutzoukas","year":"2025","journal-title":"Clin Pharmacokinet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/microorganisms9071505","article-title":"Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage?","volume":"9","author":"Roger","year":"2021","journal-title":"Microorganisms"},{"key":"B25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s12028-022-01442-1","article-title":"Incidence and predictive factors associated with beta-lactam neurotoxicity in the critically ill: a retrospective cohort study","volume":"37","author":"Haddad","year":"2022","journal-title":"Neurocrit Care"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.2147\/IDR.S555737","article-title":"Carbapenem-induced platelet abnormalities: a systematic review literature analysis of platelet abnormality caused by carbapenems","volume":"18","author":"Pan","year":"2025","journal-title":"Infect Drug Resist."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e227124","DOI":"10.1136\/bcr-2018-227124","article-title":"Meropenem-induced liver injury and beta-lactam cross-reactivity","volume":"11","author":"Tattersall","year":"2018","journal-title":"BMJ Case Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/20009666.2020.1845929","article-title":"A case of meropenem-induced liver injury and jaundice","volume":"11","author":"Cheung","year":"2021","journal-title":"J Community Hosp Intern Med Perspect."},{"key":"B29","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/cid\/ciac798","article-title":"Shorter time to drug reaction with eosinophilia and systemic symptoms (DRESS): redefining beta-lactam-associated DRESS","volume":"76","author":"Waldron","year":"2023","journal-title":"Clin Infect Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"112019","DOI":"10.1016\/j.ijscr.2025.112019","article-title":"Severe cutaneous adverse reaction to amoxicillin-clavulanate: pediatric toxic epidermal necrolysis in the Gulf: a case report and literature review","volume":"136","author":"Asiri","year":"2025","journal-title":"Int J Surg Case Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"889088","DOI":"10.3389\/fphar.2022.889088","article-title":"Generalised Weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data","volume":"13","author":"Sauzet","year":"2022","journal-title":"Front Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/10543406.2022.2154940","article-title":"Parameter estimation of Weibull distribution for the number of days between drug administration and early onset adverse event","volume":"33","author":"Ogura","year":"2023","journal-title":"J Biopharm Stat."},{"key":"B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2288-14-17","article-title":"Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases","volume":"14","author":"Leroy","year":"2014","journal-title":"BMC Med Res Methodol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin Pharmacol Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/bcp.13576","article-title":"Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database","volume":"84","author":"Rolfes","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/jcpt.13086","article-title":"Assessment of factors associated with completeness of spontaneous adverse event reporting in the United States: a comparison between consumer reports and healthcare professional reports","volume":"45","author":"Toki","year":"2020","journal-title":"J Clin Pharm Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2023","journal-title":"Front Drug Saf Regul."},{"key":"B39","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40264-025-01604-y","article-title":"Charting and sidestepping the pitfalls of disproportionality analysis","volume":"49","author":"Fusaroli","year":"2026","journal-title":"Drug Saf."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1890727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:56:42Z","timestamp":1786514202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1890727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":40,"alternative-id":["10.3389\/fmed.2026.1890727"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1890727","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1890727"}}